Zhejiang Wecome Pharmaceutical announced that the company's product Xuesaitong dispersible tablets has been selected for the national centralized procurement by the Chinese Patent Medicine Procurement Alliance (first batch expansion follow-up). The sales revenue of Xuesaitong dispersible tablets in 2024 is expected to be approximately 26 million yuan, with the revenue from the 40-tablet package being around 4.8 million yuan. During the procurement period, Medical Institutions will prioritize the use of selected medicines, which will help expand product sales scale and increase market share, positively impacting the company’s future operating performance. However, the signing of the procurement agreement for Xuesaitong dispersible tablets and subsequent matters and their impact are still uncertain.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Died at the age of 97! Lee Shau Kee, the founder of Henderson Land Development, passed away, recalling the legendary life of the 'Asian Stock God.'
What happened? China's Assets exploded across the board, and the Nasdaq China Golden Dragon Index reached a nearly two-year high.
The focus of "Reassessing Alibaba's" value: Alibaba Cloud in the AI era.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
维康药业:产品血塞通分散片中选全国中成药采购联盟集中带量采购
Zhejiang Wecome Pharmaceutical: The product Xuesaitong dispersible tablets has been selected for the national centralized procurement by the Chinese Patent Medicine Procurement Alliance.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 358
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report